Lenz Therapeutics (LENZ) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
0
Operating Income
-16.9M
Net Income
-14.6M
EPS (Diluted)
$-0.53
Balance Sheet Metrics
Total Assets
201.3M
Total Liabilities
9.2M
Shareholders Equity
192.0M
Debt to Equity
0.05
Cash Flow Metrics
Operating Cash Flow
-12.8M
Free Cash Flow
-16.2M
Revenue & Profitability Trend
Lenz Therapeutics Income Statement From 2021 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | - | 15.0M | 0 |
| Cost of Goods Sold | - | - | - | - |
| Gross Profit | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | ||||
| Research & Development | 29.8M | - | 21.1M | 4.2M |
| Selling, General & Administrative | 28.8M | - | 4.4M | 2.5M |
| Other Operating Expenses | - | - | - | - |
| Total Operating Expenses | 58.6M | 0 | 25.5M | 6.7M |
| Operating Income | -58.6M | - | -10.5M | -6.7M |
| Operating Margin % | 0.0% | 0.0% | -69.9% | 0.0% |
| Non-Operating Items | ||||
| Interest Income | 8.6M | - | - | - |
| Interest Expense | - | - | - | - |
| Other Non-Operating Income | 289.0K | - | 19.0K | -869.0K |
| Pre-tax Income | -49.8M | - | -10.5M | -7.6M |
| Income Tax | 1.0K | - | 347.0K | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -49.8M | - | -10.8M | -7.6M |
| Net Margin % | 0.0% | 0.0% | -72.1% | 0.0% |
| Key Metrics | ||||
| EBITDA | -58.6M | - | -10.5M | -6.7M |
| EPS (Basic) | $-2.34 | $-2.74 | $-0.42 | $-0.30 |
| EPS (Diluted) | $-2.34 | $-2.74 | $-0.42 | $-0.30 |
| Basic Shares Outstanding | 21281038 | 25533533 | 25533533 | 25533533 |
| Diluted Shares Outstanding | 21281038 | 25533533 | 25533533 | 25533533 |
Income Statement Trend
Lenz Therapeutics Balance Sheet From 2021 to 2024
| Metric | 2024 | 2022 | 2021 |
|---|---|---|---|
| Assets | |||
| Current Assets | |||
| Cash & Equivalents | 20.2M | 44.4M | 18.3M |
| Short-term Investments | 188.9M | - | - |
| Accounts Receivable | - | - | - |
| Inventory | - | - | - |
| Other Current Assets | 2.8M | 2.2M | 16.0K |
| Total Current Assets | 211.9M | 46.6M | 18.3M |
| Non-Current Assets | |||
| Property, Plant & Equipment | 1.3M | 245.0K | 5.0K |
| Goodwill | - | - | - |
| Intangible Assets | - | - | - |
| Long-term Investments | - | - | - |
| Other Non-Current Assets | 0 | - | - |
| Total Non-Current Assets | 3.4M | 310.0K | 12.0K |
| Total Assets | 215.3M | 47.0M | 18.3M |
| Liabilities | |||
| Current Liabilities | |||
| Accounts Payable | 4.3M | 4.8M | 460.0K |
| Short-term Debt | 567.0K | 103.0K | - |
| Current Portion of Long-term Debt | - | - | - |
| Other Current Liabilities | - | - | - |
| Total Current Liabilities | 10.4M | 9.5M | 1.3M |
| Non-Current Liabilities | |||
| Long-term Debt | 814.0K | 147.0K | 0 |
| Deferred Tax Liabilities | - | - | - |
| Other Non-Current Liabilities | - | 66.0K | - |
| Total Non-Current Liabilities | 814.0K | 61.6M | 31.3M |
| Total Liabilities | 11.2M | 71.1M | 32.5M |
| Equity | |||
| Common Stock | 1.0K | 10.0K | 1.0K |
| Retained Earnings | -145.0M | -25.3M | -14.5M |
| Treasury Stock | - | - | - |
| Other Equity | - | - | - |
| Total Shareholders Equity | 204.1M | -24.2M | -14.2M |
| Key Metrics | |||
| Total Debt | 1.4M | 250.0K | 0 |
| Working Capital | 201.5M | 37.1M | 17.1M |
Balance Sheet Composition
Lenz Therapeutics Cash Flow Statement From 2021 to 2024
| Metric | 2024 | 2022 | 2021 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | -49.8M | -10.8M | -7.6M |
| Depreciation & Amortization | 58.0K | 8.0K | 2.0K |
| Stock-Based Compensation | 6.4M | 721.0K | 196.0K |
| Working Capital Changes | -5.7M | 4.3M | 380.0K |
| Operating Cash Flow | -49.0M | -5.8M | -7.0M |
| Investing Activities | |||
| Capital Expenditures | -468.0K | -37.0K | -9.0K |
| Acquisitions | - | - | - |
| Investment Purchases | -241.9M | - | - |
| Investment Sales | 87.9M | - | - |
| Investing Cash Flow | -154.5M | -37.0K | -9.0K |
| Financing Activities | |||
| Share Repurchases | - | - | - |
| Dividends Paid | - | - | - |
| Debt Issuance | - | - | - |
| Debt Repayment | - | - | - |
| Financing Cash Flow | 195.0M | 30.1M | 22.8M |
| Free Cash Flow | -59.9M | -4.1M | -5.4M |
| Net Change in Cash | -8.5M | 24.3M | 15.8M |
Cash Flow Trend
Lenz Therapeutics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
47.98
Forward P/E
-17.59
Price to Book
5.71
Price to Sales
235.79
PEG Ratio
1.48
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-337.14%
Return on Equity
-26.25%
Return on Assets
-18.44%
Financial Health
Current Ratio
20.54
Debt to Equity
0.51
Per Share Data
EPS (TTM)
$-1.63
Book Value per Share
$7.24
Revenue per Share
$0.18
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| lenz | 1.2B | 47.98 | 5.71 | -26.25% | 0.00% | 0.51 |
| Vertex | 101.2B | 28.08 | 5.89 | 22.77% | 31.86% | 8.89 |
| Alnylam | 60.4B | -211.56 | 241.63 | -257.83% | -12.96% | 1,093.31 |
| Adaptive | 1.9B | -11.68 | 10.68 | -57.60% | -59.07% | 121.39 |
| Dyne Therapeutics | 1.9B | -3.90 | 2.63 | -61.32% | 0.00% | 21.19 |
| Harmony Biosciences | 1.9B | 10.33 | 2.38 | 27.58% | 23.42% | 22.43 |
Financial data is updated regularly. All figures are in the company's reporting currency.